This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
CD159c (NKG2C) antibodies
catalog :
130-103-635
quantity :
for 100 tests
clonality :
recombinant
host :
human
conjugate :
PE
clone name :
REA205
reactivity :
human
application :
flow cytometry
citations: 5
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
product information
Item Name :
CD159c (NKG2C) antibodies
Catalog Number :
130-103-635
Quantity :
for 100 tests
Target :
CD159c (NKG2C)
Reactivity :
human
Applications :
Flow Cytometry
Primary / Secondary :
Primary
Host :
human
Conjugate/Tag/Label :
PE
Format :
Antibodies are supplied in buffer containing stabilizer and 0.05% sodium azide.
Isotype :
recombinant human IgG1
Clone :
REA205
Clonality :
recombinant
Long text :
Clone REA205 recognizes the CD159c antigen, a calcium-dependent (C-type) lectin, which is also known as NKG2C type II integral membrane protein or KLRC2. CD159c heterodimerizes with CD94 to form a complex that recognizes HLA-E as ligand. Clone REA205 detects the human CD159c/CD94 heterodimer and does not cross-react with the human CD159a/CD94 heterodimer or with the human CD94 homodimer. CD159c is expressed primarily on natural killer (NK) cells and receptor ligation results in NK cell activation. The proportion of CD3+ T cells expressing the CD159c/CD94 complex is elevated under pathologic conditions, such as human CMV infection, active celiac disease, paroxysmal nocturnal hemoglobinuria, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Moreover, CD159c can mediate the expansion of infiltrating cytotoxic CD8+ T cells in active celiac patients. Additional information: Clone REA205 displays negligible binding to Fc receptors.
company information

Miltenyi Biotec
6125 Cornerstone Court East
San Diego, CA 92121
San Diego, CA 92121
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: USA
questions and comments